Analyze Diet
2023;

Glanders and Melioidosis

Abstract: Glanders is an infectious disease caused by Burkholderia mallei, a gram-negative aerobic nonmotile bacterium. Melioidosis is an infectious disease caused by Burkholderia pseudomallei, a gram-negative aerobic, motile bacterium. The two bacteria are closely related, and both can cause disease in animals and humans. Historically, glanders was a common disease of horses, donkeys, and mules. Melioidosis was first described as a case series of 38 patients in Rangoon, Burma, by pathologist Alfred Whitmore in 1912.
Publication Date: 2023-08-14 PubMed ID: 28846298PubMed Central: PMC2167219
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Study Guide

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article focuses on the study of the infectious diseases Glanders and Melioidosis, caused by the bacteria Burkholderia mallei and Burkholderia pseudomallei respectively, and their impact on both animals and humans.

Introduction to Glanders and Melioidosis

  • The paper introduces two major infectious diseases, Glanders and Melioidosis, caused by different species of bacteria known as Burkholderia mallei and Burkholderia pseudomallei respectively.
  • Glanders is characterized as a non-motile bacterium while Melioidosis is a motile bacterium. Both are classified as gram-negative and aerobic, meaning they do not retain the violet stain in Gram’s method and can survive in an oxygen-rich environment.

Historical Background of Glanders and Melioidosis

  • The document discusses the historical significance of these diseases. Glanders, for instance, was once a prevalent disease among animals like horses, donkeys, and mules.
  • Regarding Melioidosis, the article cites the first known description of this disease in 1912 by pathologist Alfred Whitmore, who documented a series of 38 patient cases in Rangoon, Burma.

Impact of Glanders and Melioidosis on Humans

  • In addition to affecting animals, both Glanders and Melioidosis are underlined as diseases with potential to cause health problems in humans. This confirms the zoonotic nature of these diseases, meaning they can be transmitted from animals to humans.

Cite This Article

APA
Nguyen HN, Smith ME, Hayoun MA. (2023). Glanders and Melioidosis .

Publication

Language: English

Researcher Affiliations

Nguyen, HoanVu N.
  • UC Davis Medical Center
Smith, Matthew E.
  • CBIRF
Hayoun, Michael A.
  • Tristar Healthcare Network

References

This article includes 40 references
  1. Dance D. A glanders-like disease in Rangoon: Whitmore A. J Hyg 1913; 13: 1-34. Epidemiol Infect. 2005 Oct;133 Suppl 1:S9-S10.
    pubmed: 24965251
  2. Whitmore A. An Account of a Glanders-like Disease occurring in Rangoon. J Hyg (Lond) 1913 Apr;13(1):1-34.
    pmc: PMC2167219pubmed: 20474526
  3. Jilani M S, Robayet J A, Mohiuddin M, Hasan M R, Ahsan C R, Haq J A. Burkholderia pseudomallei: Its Detection in Soil and Seroprevalence in Bangladesh. PLoS Negl Trop Dis 2016 Jan;10(1):e0004301.
    pmc: PMC4714902pubmed: 26771511
  4. Wilkinson L. Glanders: medicine and veterinary medicine in common pursuit of a contagious disease. Med Hist 1981 Oct;25(4):363-84.
    pmc: PMC1139069pubmed: 7038356
  5. Chewapreecha C, Holden M T, Vehkala M, Välimäki N, Yang Z, Harris S R, Mather A E, Tuanyok A, De Smet B, Le Hello S, Bizet C, Mayo M, Wuthiekanun V, Limmathurotsakul D, Phetsouvanh R, Spratt B G, Corander J, Keim P, Dougan G, Dance D A, Currie B J, Parkhill J, Peacock S J. Global and regional dissemination and evolution of Burkholderia pseudomallei. Nat Microbiol 2017 Jan 23;2:16263.
    pmc: PMC5300093pubmed: 28112723
  6. Limmathurotsakul D, Golding N, Dance D A, Messina J P, Pigott D M, Moyes C L, Rolim D B, Bertherat E, Day N P, Peacock S J, Hay S I. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat Microbiol 2016 Jan 01;1(1).
    pubmed: 27571754
  7. Ko W C, Cheung B M, Tang H J, Shih H I, Lau Y J, Wang L R, Chuang Y C. Melioidosis outbreak after typhoon, southern Taiwan. Emerg Infect Dis 2007 Jun;13(6):896-8.
    pmc: PMC2792857pubmed: 17553230
  8. Prakash A, Thavaselvam D, Kumar A, Kumar A, Arora S, Tiwari S, Barua A, Sathyaseelan K. Isolation, identification and characterization of Burkholderia pseudomallei from soil of coastal region of India. Springerplus 2014;3:438.
    pmc: PMC4152474pubmed: 25187882
  9. Brilhante R S, Bandeira T J, Cordeiro R A, Grangeiro T B, Lima R A, Ribeiro J F, Castelo-Branco D S, Rodrigues J L, Coelho I C, Magalhães F G, Rocha M F, Sidrim J J. Clinical-epidemiological features of 13 cases of melioidosis in Brazil. J Clin Microbiol 2012 Oct;50(10):3349-52.
    pmc: PMC3457459pubmed: 22814457
  10. Katangwe T, Purcell J, Bar-Zeev N, Denis B, Montgomery J, Alaerts M, Heyderman R S, Dance D A, Kennedy N, Feasey N, Moxon C A. Human melioidosis, Malawi, 2011. Emerg Infect Dis 2013 Jun;19(6):981-4.
    pmc: PMC3713813pubmed: 23735189
  11. Bernhards R C, Cote C K, Amemiya K, Waag D M, Klimko C P, Worsham P L, Welkos S L. Characterization of in vitro phenotypes of Burkholderia pseudomallei and Burkholderia mallei strains potentially associated with persistent infection in mice. Arch Microbiol 2017 Mar;199(2):277-301.
    pmc: PMC5306356pubmed: 27738703
  12. Varga J J, Vigil A, DeShazer D, Waag D M, Felgner P, Goldberg J B. Distinct human antibody response to the biological warfare agent Burkholderia mallei. Virulence 2012 Oct 01;3(6):510-4.
    pmc: PMC3524150pubmed: 23076276
  13. Waag D M, England M J, DeShazer D. Humoral immune responses in a human case of glanders. Clin Vaccine Immunol 2012 May;19(5):814-6.
    pmc: PMC3346324pubmed: 22398248
  14. Currie B J. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Semin Respir Crit Care Med 2015 Feb;36(1):111-25.
    pubmed: 25643275
  15. Andersen E W, Mackay M T, Ryan M M. Neurologic Melioidosis: Case Report of a Rare Cause of Acute Flaccid Paralysis. J Pediatr 2016 Mar;170:319-21.
    pubmed: 26778096
  16. Dan M, Taran D. Melioidosis of the Skin in an Israeli Traveler Returning from Thailand. Isr Med Assoc J 2015 Nov;17(11):724-5.
    pubmed: 26757575
  17. Saravu K, Kadavigere R, Shastry A B, Pai R, Mukhopadhyay C. Neurologic melioidosis presented as encephalomyelitis and subdural collection in two male labourers in India. J Infect Dev Ctries 2015 Nov 30;9(11):1289-93.
    pubmed: 26623640
  18. Guo R F, Wong F L, Perez M L. Splenic abscesses in a returning traveler. Infect Dis Rep 2015 Feb 24;7(1):5791.
    pmc: PMC4387372pubmed: 25874071
  19. Leth S, Wang M, Deutch S. [Melioidosis in a Danish tourist returning from North-eastern Thailand]. Ugeskr Laeger 2014 Jun 09;176(12).
    pubmed: 25096943
  20. Wijekoon S, Prasath T, Corea E M, Elwitigala J P. Melioidosis presenting as lymphadenitis: a case report. BMC Res Notes 2014 Jun 14;7:364.
    pmc: PMC4062509pubmed: 24927768
  21. Stephens D P, Thomas J H, Ward L M, Currie B J. Melioidosis Causing Critical Illness: A Review of 24 Years of Experience From the Royal Darwin Hospital ICU. Crit Care Med 2016 Aug;44(8):1500-5.
    pubmed: 26963328
  22. Lau S K, Sridhar S, Ho C C, Chow W N, Lee K C, Lam C W, Yuen K Y, Woo P C. Laboratory diagnosis of melioidosis: past, present and future. Exp Biol Med (Maywood) 2015 Jun;240(6):742-51.
    pmc: PMC4935216pubmed: 25908634
  23. Pal V, Saxena A, Singh S, Goel A K, Kumar J S, Parida M M, Rai G P. Development of a real-time loop-mediated isothermal amplification assay for detection of Burkholderia mallei. Transbound Emerg Dis 2018 Feb;65(1):e32-e39.
    pubmed: 28649808
  24. Zakharova I, Teteryatnikova N, Toporkov A, Viktorov D. Development of a multiplex PCR assay for the detection and differentiation of Burkholderia pseudomallei, Burkholderia mallei, Burkholderia thailandensis, and Burkholderia cepacia complex. Acta Trop 2017 Oct;174:1-8.
    pubmed: 28634144
  25. Limmathurotsakul D, Funnell S G, Torres A G, Morici L A, Brett P J, Dunachie S, Atkins T, Altmann D M, Bancroft G, Peacock S J, Steering Group on Melioidosis Vaccine Development. Consensus on the development of vaccines against naturally acquired melioidosis. Emerg Infect Dis 2015 Jun;21(6).
    pmc: PMC4451926pubmed: 25992835
  26. Hatcher C L, Muruato L A, Torres A G. Recent Advances in Burkholderia mallei and B. pseudomallei Research. Curr Trop Med Rep 2015 Jun;2(2):62-69.
    pmc: PMC4410361pubmed: 25932379
  27. Podnecky N L, Rhodes K A, Schweizer H P. Efflux pump-mediated drug resistance in Burkholderia. Front Microbiol 2015;6:305.
    pmc: PMC4396416pubmed: 25926825
  28. Cheng A C, Currie B J, Dance D A B, Funnell S G P, Limmathurotsakul D, Simpson A J H, Peacock S J. Clinical definitions of melioidosis. Am J Trop Med Hyg 2013 Mar;88(3):411-413.
    pmc: PMC3592517pubmed: 23468355
  29. Georgiades C, Fishman E K. Clinical image. Glanders disease of the liver and spleen: CT evaluation. J Comput Assist Tomogr 2001 Jan-Feb;25(1):91-3.
    pubmed: 11176300
  30. Russell P, Eley S M, Ellis J, Green M, Bell D L, Kenny D J, Titball R W. Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. J Antimicrob Chemother 2000 Jun;45(6):813-8.
    pubmed: 10837435
  31. Kenny D J, Russell P, Rogers D, Eley S M, Titball R W. In vitro susceptibilities of Burkholderia mallei in comparison to those of other pathogenic Burkholderia spp.. Antimicrob Agents Chemother 1999 Nov;43(11):2773-5.
    pmc: PMC89557pubmed: 10543761
  32. Waag D M. Efficacy of postexposure therapy against glanders in mice. Antimicrob Agents Chemother 2015 Apr;59(4):2236-41.
    pmc: PMC4356808pubmed: 25645854
  33. Heine H S, England M J, Waag D M, Byrne W R. In vitro antibiotic susceptibilities of Burkholderia mallei (causative agent of glanders) determined by broth microdilution and E-test. Antimicrob Agents Chemother 2001 Jul;45(7):2119-21.
    pmc: PMC90610pubmed: 11408233
  34. McLeod C, Morris P S, Bauert P A, Kilburn C J, Ward L M, Baird R W, Currie B J. Clinical presentation and medical management of melioidosis in children: a 24-year prospective study in the Northern Territory of Australia and review of the literature. Clin Infect Dis 2015 Jan 01;60(1):21-6.
    pubmed: 25228703
  35. Sivalingam S P, Sim S H, Jasper L C, Wang D, Liu Y, Ooi E E. Pre- and post-exposure prophylaxis of experimental Burkholderia pseudomallei infection with doxycycline, amoxicillin/clavulanic acid and co-trimoxazole. J Antimicrob Chemother 2008 Mar;61(3):674-8.
    pubmed: 18192684
  36. Sarovich D S, Ward L, Price E P, Mayo M, Pitman M C, Baird R W, Currie B J. Recurrent melioidosis in the Darwin Prospective Melioidosis Study: improving therapies mean that relapse cases are now rare. J Clin Microbiol 2014 Feb;52(2):650-3.
    pmc: PMC3911345pubmed: 24478504
  37. Chetchotisakd P, Chierakul W, Chaowagul W, Anunnatsiri S, Phimda K, Mootsikapun P, Chaisuksant S, Pilaikul J, Thinkhamrop B, Phiphitaporn S, Susaengrat W, Toondee C, Wongrattanacheewin S, Wuthiekanun V, Chantratita N, Thaipadungpanit J, Day N P, Limmathurotsakul D, Peacock S J. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet 2014 Mar 01;383(9919):807-14.
    pmc: PMC3939931pubmed: 24284287
  38. Cheng A C, Currie B J. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005 Apr;18(2):383-416.
    pmc: PMC1082802pubmed: 15831829
  39. Wolfe D N, Florence W, Bryant P. Current biodefense vaccine programs and challenges. Hum Vaccin Immunother 2013 Jul;9(7):1591-7.
    pubmed: 23428906
  40. Wheelis M. First shots fired in biological warfare. Nature 1998 Sep 17;395(6699):213.
    pubmed: 9751039